News of the various Chinese Communist virus vaccines continue, the New England Journal of Medicine (NEJM) 6 new study pointed out that Modena new crown (Chinese Communist virus) vaccine protection for at least six months, and the degree of antibodies seem to be higher in young people than in older people; while the European Union Drug Agency (EMA) said that whether AstraZeneca vaccine and blood clots have a causal relationship, but has yet to be further studied In addition, the vaccine developed by the Army started human trials on the 6th, and the preliminary results are expected to be available in mid-summer. Protection of 90%
According to the new study, the protective power of the Modena vaccine is expected to last more than six months, and antibody activity is expected to decline over time, but further information from the final clinical trial is needed to know how long the vaccine will have protective power.
Antibodies are higher in youth than in older populations
According to the NEJM study, scientists found that protective antibodies remained active in 33 adults across all age groups who participated in the preliminary study, and appeared to be more active in young adults than in older age groups.
The NEJM study echoes another report last week on the Pfizer vaccine, which showed that six months after the second dose of the Pfizer vaccine, 91.3 percent protection was still in place and 100 percent protection from severe illness was achieved, while the preliminary study by Modena showed 94.1 percent protection.
Marco Cavaleri, head of the EMA’s vaccine strategy department, said on June 6 that there is a causal relationship between the Astellicam vaccine and rare blood clots, and that although the exact association is not clear, the benefits of the vaccine outweigh the drawbacks for now.
Cavaleri said that based on current evidence, it is becoming increasingly difficult to prove that there is no causal relationship between the Astellicam vaccine and rare blood clots; this is the first time that international regulators have hinted that the vaccine may have rare blood clot side effects.
Army develops vaccine for human trials
In the United States, the Army developed a new crown (Chinese communist virus) vaccine 6 began human trials, 72 adults between the ages of 18 and 55 at the Walter Reed Army Institute of Research in Maryland were vaccinated with the protein vaccine to understand whether the vaccine can safely trigger an appropriate immune response in the human body. Preliminary trial results are expected by mid-summer.
The Army researchers said their vaccine was protective in monkey tests and laboratory tests showed the vaccine could protect against the more infectious New Guinea virus variant; if the human trials are successful, the vaccine is expected to be used in additional vaccines and expanded to include all military personnel.
Recent Comments